InvestorsHub Logo
Followers 20
Posts 5331
Boards Moderated 0
Alias Born 01/04/2012

Re: None

Monday, 07/15/2013 10:19:14 PM

Monday, July 15, 2013 10:19:14 PM

Post# of 26138
According to the Wall Street Journal - Sandra J. Croak-Brossman is back with BPAX (Probably ANI right after the R/S) VP-Regulatory Affairs & Quality Assurance.

Look under all BPAX executives. You will notice that many others are gone but she is still here.

BPAX

Snabes gone to Abbvie, Croak-Brossman comes over from Abbott around the time the CV patent applications are filed. Nothing ever divulged about the CV findings. According to Simes he tried to keep her but to no avail and he stated he had the utmost respect for her.

They would have a very hard time convincing a jury that this was not part of a plan orchestrated by Abbott and Abbvie. Especially when you look at the timing of Linda Andrews being hired by Abbott shortly after they hired Croak-Brossman (both were long time employees at Pfizer). Then the timing of Linda Andrews coming over from Abbott in relation and to the changes to the safety and clinical trials in Libigel.

The fact Linda Andrews changed her work experience to mislead people into thinking that is very incriminating evidence. Especially when we know full well that according to her work experience (posted June 23, 2012)that August 2009 she is hired by Abbott. Then between November 2009 and March 2010 (5 months) she apparently worked for both Abbott and Biosante and not as a contractor. Then from March 2010 onward she has remained with Abbott and moved upward in the company.

More on Linda Andrews

November 12, 2009, not only recorded changes to the Libigel trials. It also recorded significant changes to the Androgel Testosterone trial for older men.

Testosterone trial for older men changes

I will have to research but Abbott appears to have started funding the CDC for improved Testosterone testing (low dose T testing)around this time.

One question which remains to be answered "Is Pfizer involved?"

Much speculation has revolved around Abbvie and Pfizer merging, however from what I have read it appears for taxation purposes this can not happen until January 1, 2015, at the earliest.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.